Peter Brojde Lung Cancer Center, Jewish General Hospital, McGill University, Montreal, QC H3T1E2, Canada.
Department of Oncology, McGill University, Montreal, QC H3T1E2, Canada.
Curr Oncol. 2021 Oct 20;28(6):4247-4255. doi: 10.3390/curroncol28060360.
The large burden of COVID-19 on health care systems worldwide has raised concerns among medical oncologists about the impact of COVID-19 on the diagnosis and treatment of lung cancer patients. In this retrospective cohort study, we investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and during the COVID-19 era. New lung cancer diagnoses decreased by 34.7% during the pandemic with slightly more advanced stages of disease, there was a significant increase in the utilization of radiosurgery as the first definitive treatment, and a decrease in both systemic treatment as well as surgery compared to the pre-COVID-19 era. There was no significant delay in starting chemotherapy and radiation treatment during the pandemic compared to pre-COVID-19 time. However, we observed a delay to lung cancer surgery during the pandemic time. COVID-19 seems to have had a major impact at our lung cancer center on the diagnoses and treatment patterns of lung cancer patients. Many oncologists fear that they will see an increase in newly diagnosed lung cancer patients in the coming year. This study is still ongoing and further data will be collected and analyzed to better understand the total impact of the COVID-19 pandemic on our lung cancer patient population.
COVID-19 给全球医疗体系带来了巨大负担,这让肿瘤内科医生对 COVID-19 对肺癌患者的诊断和治疗的影响感到担忧。在这项回顾性队列研究中,我们研究了 COVID-19 大流行前后对肺癌诊断和治疗的影响。大流行期间新诊断的肺癌病例减少了 34.7%,疾病分期略为晚期,放射外科治疗作为一线确定性治疗的应用显著增加,与 COVID-19 前时期相比,系统治疗和手术都有所减少。与 COVID-19 前时期相比,大流行期间化疗和放疗的开始时间并没有明显延迟。然而,我们观察到在大流行期间肺癌手术有所延迟。COVID-19 似乎对我们的肺癌中心的肺癌患者的诊断和治疗模式产生了重大影响。许多肿瘤学家担心,在未来一年中,他们将看到新诊断的肺癌患者数量增加。这项研究仍在进行中,将收集和分析更多的数据,以更好地了解 COVID-19 大流行对我们的肺癌患者群体的总体影响。